Related references
Note: Only part of the references are listed.Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study
Rohit Loomba et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2023)
Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats
Erik J. Tillman et al.
BRITISH JOURNAL OF PHARMACOLOGY (2022)
Adiponectin forms a complex with atherogenic LDL and inhibits its downstream effects
Akemi Kakino et al.
JOURNAL OF LIPID RESEARCH (2021)
FGF21 Mimics a Fasting-Induced Metabolic State and Increases Appetite in Zebrafish
Ayelen Melisa Blanco et al.
SCIENTIFIC REPORTS (2020)
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic
Leiluo Geng et al.
NATURE REVIEWS ENDOCRINOLOGY (2020)
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Audrey Deprince et al.
MOLECULAR METABOLISM (2020)
FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
Erik J. Tillman et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Epidemiology of non-alcoholic fatty liver disease and risk of hepatocellular carcinoma progression
Krishna Chaitanya Thandra et al.
CLINICAL AND EXPERIMENTAL HEPATOLOGY (2020)
Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans
Amos Baruch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
FGF21 decreases food intake and body weight in obese Gottingen minipigs
Berit Christoffersen et al.
DIABETES OBESITY & METABOLISM (2019)
The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View
Christina C. Lindenmeyer et al.
CLINICS IN LIVER DISEASE (2018)
FGF21 decreases body weight without reducing food intake or bone mineral density in high-fat fed obese rhesus macaque monkeys
Birgitte Andersen et al.
INTERNATIONAL JOURNAL OF OBESITY (2018)
Link between FGF21 and blood pressure
Claire Greenhill
NATURE REVIEWS ENDOCRINOLOGY (2018)
Severe hypertriglyceridemia in Norway: prevalence, clinical and genetic characteristics
Kjetil Retterstol et al.
LIPIDS IN HEALTH AND DISEASE (2017)
Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma
Changhoon Yoo et al.
ONCOTARGET (2017)
FGF21 resistance is not mediated by downregulation of beta-klotho expression in white adipose tissue
Kathleen R. Markan et al.
MOLECULAR METABOLISM (2017)
Fibroblast growth factor 21, assisted by elevated glucose, activates paraventricular nucleus NUCB2/Nesfatin-1 neurons to produce satiety under fed states
Putra Santoso et al.
SCIENTIFIC REPORTS (2017)
FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms
Lucas BonDurant et al.
CELL METABOLISM (2017)
Circulating FGF21 proteolytic processing mediated by fibroblast activation protein
Eugene Y. Zhen et al.
BIOCHEMICAL JOURNAL (2016)
A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects
Saswata Talukdar et al.
CELL METABOLISM (2016)
FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues
Christian Schlein et al.
CELL METABOLISM (2016)
Nonalcoholic Fatty Liver Disease Pathophysiology and Management
Rotonya M. Carr et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2016)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
The Natural Course of Non-Alcoholic Fatty Liver Disease
Luis Calzadilla Bertot et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates
W. Clayton Thompson et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2016)
The FGF21-adiponectin axis in controlling energy and vascular homeostasis
Xiaoyan Hui et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2016)
Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
Robert J. Wong et al.
GASTROENTEROLOGY (2015)
Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Erin K. Spengler et al.
MAYO CLINIC PROCEEDINGS (2015)
The Fibroblast Growth Factor signaling pathway
David M. Ornitz et al.
WILEY INTERDISCIPLINARY REVIEWS-DEVELOPMENTAL BIOLOGY (2015)
Non-alcoholic fatty liver disease: The diagnosis and management
Shehab M. Abd El-Kader et al.
WORLD JOURNAL OF HEPATOLOGY (2015)
An FGF21-Adiponectin-Ceramide Axis Controls Energy Expenditure and Insulin Action in Mice
William L. Holland et al.
CELL METABOLISM (2013)
Analytical Measurement of PEGylated Molecules
Tian-Lu Cheng et al.
BIOCONJUGATE CHEMISTRY (2012)
FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents
James Mu et al.
DIABETES (2012)
Fundamentals of FGF19 & FGF21 Action In Vitro and In Vivo
Andrew C. Adams et al.
PLOS ONE (2012)
The starvation hormone, fibroblast growth factor-21, extends lifespan in mice
Yuan Zhang et al.
ELIFE (2012)
Prevalence of Severe (500 to 2,000 mg/dl) Hypertriglyceridemia in United States Adults
Jennifer B. Christian et al.
AMERICAN JOURNAL OF CARDIOLOGY (2011)
Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis
Stergios A. Polyzos et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2011)
A Better Anti-Diabetic Recombinant Human Fibroblast Growth Factor 21 (rhFGF21) Modified with Polyethylene Glycol
Zhifeng Huang et al.
PLOS ONE (2011)
Fibroblast Growth Factor 21 Action in the Brain Increases Energy Expenditure and Insulin Sensitivity in Obese Rats
David A. Sarruf et al.
DIABETES (2010)
Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
Ffolliott M. Fisher et al.
DIABETES (2010)
The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease
Stergios A. Polyzos et al.
DIABETES OBESITY & METABOLISM (2010)
Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19)
Xinle Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice
Jing Xu et al.
DIABETES (2009)
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Tamer Coskun et al.
ENDOCRINOLOGY (2008)
The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
Alexei Kharitonenkov et al.
ENDOCRINOLOGY (2007)
FGF-21 as a novel metabolic regulator
A Kharitonenkov et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Plasma adiponectin is decreased in nonalcoholic fatty liver disease
C Pagano et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Adiponectin, obesity, and cardiovascular disease
M Fasshauer et al.
BIOCHIMIE (2004)
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report
SM Grundy et al.
CIRCULATION (2002)
Share Paper
